HER2-negative Breast Cancer Clinical Trials

153 clinical trials for HER2-negative Breast Cancer across international registries, including 60 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study — RECRUITING · PHASE2
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) — RECRUITING · PHASE3
• Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer — RECRUITING · PHASE2
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs — RECRUITING · PHASE2
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment — RECRUITING · PHASE3
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — RECRUITING · PHASE3
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors — RECRUITING · PHASE1
• Sacituzumab Govitecan In TNBC — RECRUITING · PHASE2
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer — RECRUITING · PHASE2
• CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment — RECRUITING · PHASE2
• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer — RECRUITING · PHASE2
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer — RECRUITING · PHASE1
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer — RECRUITING · PHASE1
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer — RECRUITING · PHASE1
• A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer — RECRUITING · PHASE2
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) — RECRUITING · PHASE2
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients — RECRUITING
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer — RECRUITING · PHASE1
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy — RECRUITING · PHASE2
• Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy — RECRUITING · PHASE2
• Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy — RECRUITING · PHASE1
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer — RECRUITING · PHASE2
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer — RECRUITING · PHASE2
• A Study of the TheraBionic P1 Device in Breast Cancer — RECRUITING · NA
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer — RECRUITING · PHASE2
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — RECRUITING · PHASE3
• Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer — RECRUITING
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer — RECRUITING · PHASE2
• Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer — RECRUITING
• NearWave Optical Molecular Monitoring — RECRUITING · NA
• Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib — RECRUITING · PHASE2
• DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer — RECRUITING · PHASE1
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells — RECRUITING · PHASE1
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer — RECRUITING · PHASE2
• Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer — RECRUITING · PHASE2
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas — RECRUITING · PHASE1
• Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer — RECRUITING
• Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer — RECRUITING · PHASE1
• Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis — RECRUITING · PHASE4
• Reverse HER2-negative Immune Resistant Breast Cancer — RECRUITING · PHASE2
• Breast Re-irradiation After Second Ipsilateral Lumpectomy — RECRUITING · NA
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd — RECRUITING · PHASE2
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer — RECRUITING · PHASE1
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — RECRUITING · PHASE1
• Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer — RECRUITING
• Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer — RECRUITING · PHASE1
• Role of the Immune Environment in Response to Therapy in Breast Cancer — RECRUITING
• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer — RECRUITING · PHASE2

Refine this search